Cargando…

A Unique Role of GATA1s in Down Syndrome Acute Megakaryocytic Leukemia Biology and Therapy

BACKGROUND: Acute megakaryocytic leukemia (AMkL) in Down syndrome (DS) children is uniformly associated with somatic GATA1 mutations, which result in the synthesis of a shorter protein (GATA1s) with altered transactivation activity compared to the wild-type GATA1. It is not fully established whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Xavier, Ana C., Edwards, Holly, Dombkowski, Alan A., Balci, Tugce B., Berman, Jason N., Dellaire, Graham, Xie, Chengzhi, Buck, Steven A., Matherly, Larry H., Ge, Yubin, Taub, Jeffrey W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217966/
https://www.ncbi.nlm.nih.gov/pubmed/22110660
http://dx.doi.org/10.1371/journal.pone.0027486
_version_ 1782216642643623936
author Xavier, Ana C.
Edwards, Holly
Dombkowski, Alan A.
Balci, Tugce B.
Berman, Jason N.
Dellaire, Graham
Xie, Chengzhi
Buck, Steven A.
Matherly, Larry H.
Ge, Yubin
Taub, Jeffrey W.
author_facet Xavier, Ana C.
Edwards, Holly
Dombkowski, Alan A.
Balci, Tugce B.
Berman, Jason N.
Dellaire, Graham
Xie, Chengzhi
Buck, Steven A.
Matherly, Larry H.
Ge, Yubin
Taub, Jeffrey W.
author_sort Xavier, Ana C.
collection PubMed
description BACKGROUND: Acute megakaryocytic leukemia (AMkL) in Down syndrome (DS) children is uniformly associated with somatic GATA1 mutations, which result in the synthesis of a shorter protein (GATA1s) with altered transactivation activity compared to the wild-type GATA1. It is not fully established whether leukemogenesis and therapeutic responses in DS AMkL patients are due to loss of the wild-type GATA1 or due to a unique function of GATA1s. METHODOLOGY: Stable clones of CMK cells with decreased GATA1s or Bcl-2 levels were generated by using GATA1- or BCL-2-specific lentivirus shRNAs. In vitro ara-C, daunorubicin, and VP-16 cytotoxicities of the shRNA stable clones were determined by using the Cell Titer-blue reagent. Apoptosis and cell cycle distribution were determined by flow cytometry analysis. Changes in gene transcript levels were determined by gene expression microarray and/or real-time RT-PCR. Changes in protein levels were measured by Western blotting. In vivo binding of GATA1s to IL1A promoter was determined by chromatin immunoprecipitation assays. RESULTS: Lentivirus shRNA knockdown of the GATA1 gene in the DS AMkL cell line, CMK (harbors a mutated GATA1 gene and only expresses GATA1s), resulting in lower GATA1s protein levels, promoted cell differentiation towards the megakaryocytic lineage and repressed cell proliferation. Increased basal apoptosis and sensitivities to ara-C, daunorubicin, and VP-16 accompanied by down-regulated Bcl-2 were also detected in the CMK GATA1 shRNA knockdown clones. Essentially the same results were obtained when Bcl-2 was knocked down with lentivirus shRNA in CMK cells. Besides Bcl-2, down-regulation of GATA1s also resulted in altered expression of genes (e.g., IL1A, PF4, and TUBB1) related to cell death, proliferation, and differentiation. CONCLUSION: Our results suggest that GATA1s may facilitate leukemogenesis and potentially impact therapeutic responses in DS AMkL by promoting proliferation and survival, and by repressing megakaryocytic lineage differentiation, potentially by regulating expression of Bcl-2 protein and other relevant genes.
format Online
Article
Text
id pubmed-3217966
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32179662011-11-21 A Unique Role of GATA1s in Down Syndrome Acute Megakaryocytic Leukemia Biology and Therapy Xavier, Ana C. Edwards, Holly Dombkowski, Alan A. Balci, Tugce B. Berman, Jason N. Dellaire, Graham Xie, Chengzhi Buck, Steven A. Matherly, Larry H. Ge, Yubin Taub, Jeffrey W. PLoS One Research Article BACKGROUND: Acute megakaryocytic leukemia (AMkL) in Down syndrome (DS) children is uniformly associated with somatic GATA1 mutations, which result in the synthesis of a shorter protein (GATA1s) with altered transactivation activity compared to the wild-type GATA1. It is not fully established whether leukemogenesis and therapeutic responses in DS AMkL patients are due to loss of the wild-type GATA1 or due to a unique function of GATA1s. METHODOLOGY: Stable clones of CMK cells with decreased GATA1s or Bcl-2 levels were generated by using GATA1- or BCL-2-specific lentivirus shRNAs. In vitro ara-C, daunorubicin, and VP-16 cytotoxicities of the shRNA stable clones were determined by using the Cell Titer-blue reagent. Apoptosis and cell cycle distribution were determined by flow cytometry analysis. Changes in gene transcript levels were determined by gene expression microarray and/or real-time RT-PCR. Changes in protein levels were measured by Western blotting. In vivo binding of GATA1s to IL1A promoter was determined by chromatin immunoprecipitation assays. RESULTS: Lentivirus shRNA knockdown of the GATA1 gene in the DS AMkL cell line, CMK (harbors a mutated GATA1 gene and only expresses GATA1s), resulting in lower GATA1s protein levels, promoted cell differentiation towards the megakaryocytic lineage and repressed cell proliferation. Increased basal apoptosis and sensitivities to ara-C, daunorubicin, and VP-16 accompanied by down-regulated Bcl-2 were also detected in the CMK GATA1 shRNA knockdown clones. Essentially the same results were obtained when Bcl-2 was knocked down with lentivirus shRNA in CMK cells. Besides Bcl-2, down-regulation of GATA1s also resulted in altered expression of genes (e.g., IL1A, PF4, and TUBB1) related to cell death, proliferation, and differentiation. CONCLUSION: Our results suggest that GATA1s may facilitate leukemogenesis and potentially impact therapeutic responses in DS AMkL by promoting proliferation and survival, and by repressing megakaryocytic lineage differentiation, potentially by regulating expression of Bcl-2 protein and other relevant genes. Public Library of Science 2011-11-16 /pmc/articles/PMC3217966/ /pubmed/22110660 http://dx.doi.org/10.1371/journal.pone.0027486 Text en Xavier et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Xavier, Ana C.
Edwards, Holly
Dombkowski, Alan A.
Balci, Tugce B.
Berman, Jason N.
Dellaire, Graham
Xie, Chengzhi
Buck, Steven A.
Matherly, Larry H.
Ge, Yubin
Taub, Jeffrey W.
A Unique Role of GATA1s in Down Syndrome Acute Megakaryocytic Leukemia Biology and Therapy
title A Unique Role of GATA1s in Down Syndrome Acute Megakaryocytic Leukemia Biology and Therapy
title_full A Unique Role of GATA1s in Down Syndrome Acute Megakaryocytic Leukemia Biology and Therapy
title_fullStr A Unique Role of GATA1s in Down Syndrome Acute Megakaryocytic Leukemia Biology and Therapy
title_full_unstemmed A Unique Role of GATA1s in Down Syndrome Acute Megakaryocytic Leukemia Biology and Therapy
title_short A Unique Role of GATA1s in Down Syndrome Acute Megakaryocytic Leukemia Biology and Therapy
title_sort unique role of gata1s in down syndrome acute megakaryocytic leukemia biology and therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217966/
https://www.ncbi.nlm.nih.gov/pubmed/22110660
http://dx.doi.org/10.1371/journal.pone.0027486
work_keys_str_mv AT xavieranac auniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT edwardsholly auniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT dombkowskialana auniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT balcitugceb auniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT bermanjasonn auniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT dellairegraham auniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT xiechengzhi auniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT buckstevena auniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT matherlylarryh auniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT geyubin auniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT taubjeffreyw auniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT xavieranac uniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT edwardsholly uniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT dombkowskialana uniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT balcitugceb uniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT bermanjasonn uniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT dellairegraham uniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT xiechengzhi uniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT buckstevena uniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT matherlylarryh uniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT geyubin uniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy
AT taubjeffreyw uniqueroleofgata1sindownsyndromeacutemegakaryocyticleukemiabiologyandtherapy